Prevention of type 1a diabetes mellitus

Pediatric Diabetes

Volumn 2, Issue 1, 2001, Pages 17-24

  Wilson, Darrell M ^a   Buckingham, Bruce ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Autoimmune diseases; Diabetes mellitus; Insulin; Insulin dependent; Nicotinamide; Prevention and control

Indexed keywords

AUTOANTIBODY; CYTOKINE; EPITOPE; HLA DQ ANTIGEN; INSULIN; INSULIN ZINC SUSPENSION; MONOCLONAL ANTIBODY; NICOTINAMIDE; PLACEBO;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ARTIFICIAL MILK; AUTOIMMUNITY; BREAST FEEDING; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GENETIC PREDISPOSITION; HIGH RISK PATIENT; HLA TYPING; HUMAN; INFANCY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INTRAVENOUS GLUCOSE TOLERANCE TEST; MOUSE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELATIVE; REVIEW; SCREENING; SUPPLEMENTATION;

EID: 0035037358     PISSN: 1399543X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1399-543x.2001.020104.x     Document Type: Review

References (58)

1. Report of the expert committee on the diagnosis and classification of diabetes mellitus
2. Immune intervention in type I diabetes mellitus
3. Putative environmental factors in Type 1 diabetes
4. Multiple genes/multiple autoantigens role in type 1 diabetes
5. Nicotinamide in type 1 diabetes. Mechanism of action revisited
6. Molecular mechanisms of beta-cell destruction in IDDM: The role of nicotinamide
7. Poly (ADP-ribose) polymerase gene disruption conferred mice resistant to streptozotocin-induced diabetes
8. Mice lacking the poly (ADP-ribose) polymerase gene are resistant to pancreatic beta-cell destruction and diabetes development induced by streptozocin
9. Poly (ADP-ribose) polymerase-deficient mice are protected from streptozotocin-induced diabetes
10. Protection from nicotinamide inhibition of interleukin-1 beta-induced RIN cell nitric oxide formation is associated with induction of MnSOD enzyme activity
11. Pancreatic B cells possess defense mechanisms against cell-specific toxicity
12. Oxygen radicals generated by the enzyme xanthine oxidase lyse rat pancreatic islet cells in vitro
13. Nicotinamide decreases MHC class II but not MHC class I expression and increases intercellular adhesion molecule-1 structures in non-obese diabetic mouse pancreas
14. Prevention of diabetes in the NOD mouse: Implications for therapeutic intervention in human disease
15. The potential role of nicotinamide in the secondary prevention of IDDM
16. Pilot trial to prevent type I diabetes: Progression to overt IDDM despite oral nicotinamide
17. Prevention or delay of type 1 (insulin-dependent) diabetes mellitus in children using nicotinamide
18. Nicotinamide treatment in subjects at high risk of developing IDDM improves insulin secretion
19. A population based strategy to prevent insulin-dependent diabetes using nicotinamide
20. The Deutsche Nicotinamide Intervention Study: An attempt to prevent type 1 diabetes
21. Workshop on future directions in prevention of type 1 diabetes
22. Feasibility of a randomized double-blind trial aiming at avoidance of cow's milk in infancy: The TRIGR project
23. Modulation of the appearance of diabetes associated autoantibodies in the nutritional prevention of Type 1 diabetes (TRIGR) project
24. Clinical trials of cyclosporin in IDDM
25. Long-term results of early cyclosporin therapy in juvenile IDDM
26. Lessons learned from use of cyclosporine for insulin-dependent diabetes mellitus. The case for immunotherapy for insulin-dependent diabetics having residual insulin secretion
27. First-degree relatives of patients with type I diabetes mellitus. Islet-cell antibodies and abnormal insulin secretion
28. Predicting type I diabetes
29. Reduction of diabetes incidence of BB Wistar rats by early prophylactic insulin treatment of diabetes-prone animals
30. Insulin injections prevent diabetes in bio-breeding/Worcester (BB/Wor) rats
31. Diabetes prevention in BB rats by inhibition of endogenous insulin secretion
32. Insulin treatment prevents diabetes mellitus but not thyroiditis in RT6- depleted diabetes resistant BB/Wor rats
33. Insulitis and diabetes in NOD mice reduced by prophylactic insulin therapy
34. Insulin prevents adoptive cell transfer of diabetes in the autoimmune non-obese diabetic mouse
35. A randomized trial of intensive insulin therapy in newly diagnosed insulin-dependent diabetes mellitus
36. Insulin prophylaxis in individuals at high risk of type I diabetes
37. Delay of type I diabetes in high risk, first degree relatives by parenteral antigen administration: The Schwabing Insulin Prophylaxis Pilot Trial
38. Oral tolerance: Immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens
39. Oral administration of the immunodominant B-chain of insulin reduces diabetes in a co-transfer model of diabetes in the NOD mouse and is associated with a switch from Th1 to Th2 cytokines
40. Oral administration of human insulin to NOD mice generates CD4+ T cells that suppress adoptive transfer of diabetes
41. Suppression of insulitis in non-obese diabetic (NOD) mice by oral insulin administration is associated with selective expression of interleukin-4 and -10, transforming growth factor-beta, and prostaglandin-E
42. Oral tolerance for the treatment of autoimmune diseases
43. Islet cell antibody-positive relatives with human leukocyte antigen DQA1*0102, DQB1*0602: Identification by the Diabetes Prevention Trial- type 1
44. Undiagnosed hyperglycemia in relatives of type 1 diabetes patients
45. Silent type 1 diabetes
46. No difference in insulin sensitivity between 'silent' type 1 diabetes, diabetes prevention trial-type 1, and control subjects
47. First phase insulin release (FPIR) during the initial intravenous glucose tolerance test (IV-GTT) in the Diabetes Prevention Trial (DPT-1)
48. The DPT-1 intravenous insulin infusion causes temporary inhibition of basal beta cell secretion in normal human subjects
49. Environmental stress and infectious disease. Do they predict ICA status among adults participating in DPT-1?
50. Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: A multicentre randomised controlled trial
51. No effect of oral insulin on residual beta-cell function in recent- onset type I diabetes (the IMDIAB VII)
52. Autoreactive T cell responses in insulin-dependent (Type 1) diabetes mellitus. Report of the first international workshop for standardization of T cell assays
53. Effects of age duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: Observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT)
54. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial: A randomized, controlled trial
55. Prevention Insulin-Dependent Diabetes Mellitus
56. In vivo imaging of insulitis in autoimmune diabetes
57. In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis
58. Aberrant expression of HLA-DR antigens by insulin-containing beta-cells in recent-onset type I diabetes mellitus